Medscape8d
Nemolizumab Shows Lasting Benefits in Prurigo Nodularis
Long-term nemolizumab use reduces itch, disease severity, and steroid dependence in patients with prurigo nodularis in a ...
Healio22d
‘Landmark’ study shows potential of ruxolitinib cream 1.5% for prurigo nodularis
Currently, there are no approved topicals for the treatment of prurigo nodularis. According to the presenter, ruxolitinib cream 1.5% could become the first. ORLANDO — Ruxolitinib cream 1.5% ...
Medpage Today on MSN22d
Topical JAK Inhibitor Active in Itchy Prurigo Nodularis
ORLANDO -- More than 40% of patients with longstanding prurigo nodularis (PN) had significant improvement within 3 months of ...
Medscape16d
Topical Ruxolitinib Improves Itch, Blistering in Prurigo Nodularis in Study
ORLANDO, Fla. — The topical Janus tyrosine kinase (JAK) 1/2 inhibitor ruxolitinib improved itching and nodules in patients with prurigo nodularis (PN) significantly better than a vehicle within ...
PMLiVE29d
MHRA approves Galderma’s Nemluvio to treat atopic dermatitis and prurigo nodularis
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Galderma’s Nemluvio (nemolizumab) to treat both atopic dermatitis and prurigo nodularis. The UK regulator has specifically ...
Press Release: Dupixent approved as the first-ever biologic medicine in Japan for patients with COPD
Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...
Business Wire1mon
AAD 2025: Galderma to Present Extensive Updates From Across Its Dermatology Portfolio, Demonstrating Its Category Leadership and Strong Momentum
“We’re bringing impactful new science to this year’s AAD meeting, with new data on Nemluvio – our treatment for prurigo nodularis and atopic dermatitis – and the latest from our ...